Duchenne Muscular Dystrophy Market to Propel at a Significant CAGR by 2032, Assesses DelveInsight | Key Companies - Pfizer, Santhera, Taiho, FibroGen, Sarepta, Capricor, Daiichi Sankyo, Solid Biosciences
September 27, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Duchenne Muscular Dystrophy Market to Propel at a Significant CAGR by 2032, Assesses DelveInsight | Key Companies - Pfizer, Santhera, Taiho,...
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 16:17 ET
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
July 24, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
May 30, 2023 05:00 ET
|
AKAMPION
FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the...
Muscular Dystrophy Association Announces Nearly $400K in Research Grants to Address Challenges in Duchenne Muscular Dystrophy Gene Therapy
March 13, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, NY, March 13, 2023 (GLOBE NEWSWIRE) -- Today, Muscular Dystrophy Association (MDA) announced two research grants designed to address potential transgene-triggered safety concerns in...
Muscular Dystrophy Association’s Venture Philanthropy Program Announces Investment in Non-viral Gene Therapy
January 25, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announces a $650,000 investment in Myosana Therapeutics via its MDA Venture Philanthropy (MVP) program....
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
November 28, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of...
FibroGen Reports Third Quarter 2022 Financial Results
November 07, 2022 16:01 ET
|
FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
FibroGen to Participate at Stifel 2022 Healthcare Conference
November 01, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
FibroGen to Report Third Quarter 2022 Financial Results
October 24, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also...